SCHEMBL11943587

SCHEMBL11943587

CCOCCCNc1c(N2CCN(C(=O)CN)[C@@H](C)C2)cnn(-c2ccccc2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 3/20 0.38
ALDH1A1 P00352 3/20 0.38
RXFP1 Q9HBX9 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
POLB P06746 2/20 0.36
HTT P42858 1/20 0.36
MAPT P10636 1/20 0.36
CHRM4 P08173 6/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
KDM4E B2RXH2 1/20 0.36
RAB9A P51151 1/20 0.36
TSHR P16473 2/20 0.36
LMNA P02545 1/20 0.35
KMT2A Q03164 1/20 0.35
CTSB P07858 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943590 0.87 ALDH1A1 (0.47) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943612 0.83 MAPT (0.41) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943581 0.83 ALDH1A1 (0.46) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943617 0.82 MAPT (0.40) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943595 0.82 MAPT (0.41) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943532 0.81 MAPT (0.43) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL13304479 0.80 SMN1; SMN2 (0.55) DCTPP1ALDH1A1RXFP1L3MBTL1POLB
SCHEMBL11943588 0.80 ALDH1A1 (0.49) DCTPP1ALDH1A1RXFP1L3MBTL1HTT
SCHEMBL11943596 0.79 GCKR (0.41) DCTPP1ALDH1A1RXFP1POLBHTT
SCHEMBL11943584 0.79 ALDH1A1 (0.46) DCTPP1ALDH1A1RXFP1L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA DCTPP1 625/4885ALDH1A1 2437/4885RXFP1 3786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.